An Open-Label, Single-Arm, Multi-Center Phase II Study to Evaluate the Efficacy and Safety of AUY922 in Combination with Trastuzumab Standard Therapy as Second-Line Treatment in Patients with HER2-positive Advanced Gastric Cancer (CAUY922A2205).

Trial Profile

An Open-Label, Single-Arm, Multi-Center Phase II Study to Evaluate the Efficacy and Safety of AUY922 in Combination with Trastuzumab Standard Therapy as Second-Line Treatment in Patients with HER2-positive Advanced Gastric Cancer (CAUY922A2205).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Luminespib (Primary) ; Trastuzumab
  • Indications Gastric cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 21 Feb 2014 Status changed from completed to discontinued, as per ClinicalTrials.gov record.
    • 18 Feb 2014 Status changed from discontinued to completed, as per ClinicalTrials.gov record.
    • 29 Jan 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top